Display options
Cite
Gyorki DE, Callahan M, Wolchok JD, et al. The delicate balance of melanoma immunotherapy. Clin Transl Immunology. 2013;2(8):e5doi: 10.1038/cti.2013.5.
Gyorki, D. E., Callahan, M., Wolchok, J. D., & Ariyan, C. E. (2013). The delicate balance of melanoma immunotherapy. Clinical & translational immunology, 2(8), e5. https://doi.org/10.1038/cti.2013.5
Gyorki, David E, et al. "The delicate balance of melanoma immunotherapy." Clinical & translational immunology vol. 2,8 (2013): e5. doi: https://doi.org/10.1038/cti.2013.5
Gyorki DE, Callahan M, Wolchok JD, Ariyan CE. The delicate balance of melanoma immunotherapy. Clin Transl Immunology. 2013 Aug 09;2(8):e5. doi: 10.1038/cti.2013.5. eCollection 2013 Aug. PMID: 25505953; PMCID: PMC4232053.
Copy Download .nbib Format: NLM
Share it on

Clin Transl Immunology. 2013 Aug 09;2(8):e5. doi: 10.1038/cti.2013.5. eCollection 2013 Aug.

The delicate balance of melanoma immunotherapy.

Clinical & translational immunology

David E Gyorki, Margaret Callahan, Jedd D Wolchok, Charlotte E Ariyan

Affiliations

  1. Memorial Sloan-Kettering Cancer Center , New York, NY, USA.
  2. Memorial Sloan-Kettering Cancer Center , New York, NY, USA ; Ludwig Center, Memorial Sloan-Kettering Cancer Center , New York, NY, USA.
  3. Memorial Sloan-Kettering Cancer Center , New York, NY, USA ; Ludwig Center, Memorial Sloan-Kettering Cancer Center , New York, NY, USA ; Weill Cornell Medical College , New York, NY, USA.
  4. Memorial Sloan-Kettering Cancer Center , New York, NY, USA ; Weill Cornell Medical College , New York, NY, USA.

PMID: 25505953 PMCID: PMC4232053 DOI: 10.1038/cti.2013.5

Abstract

The strategy of immune modulation for the treatment of cancer is being refined with the introduction of multiple new therapeutic agents into the clinic. Melanoma is a disease where many of these agents have demonstrated efficacy. The mechanisms of action of these agents exploit the counter-regulatory mechanisms of the immune response. However, these agents are also associated with immune-related adverse events (IRAEs), which represent tissue-specific inflammatory responses. These IRAEs highlight the delicate balance of immunologic homeostasis and, with some interventions, may occur more frequently in patients who sustain a therapeutic response. This review will discuss melanoma immunogenicity and immunotherapy. Furthermore, the spectrum and distinction between a reversible immune adverse event and autoimmunity will be highlighted.

Keywords: checkpoint blockade; immunity; immunotherapy; melanoma; tumor-infiltrating lymphocytes

References

  1. N Engl J Med. 2003 Feb 6;348(6):567-8 - PubMed
  2. J Clin Oncol. 2006 Jul 1;24(19):3164-71 - PubMed
  3. N Engl J Med. 2013 Jul 11;369(2):122-33 - PubMed
  4. J Invest Dermatol. 1995 Nov;105(5):683-6 - PubMed
  5. Blood. 2009 Aug 20;114(8):1537-44 - PubMed
  6. Cancer Immunol Res. 2013 Jul;1(1):32-42 - PubMed
  7. Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4275-80 - PubMed
  8. Cell Cycle. 2009 Jun 15;8(12):1930-4 - PubMed
  9. Nat Immunol. 2002 Nov;3(11):991-8 - PubMed
  10. Adv Cancer Res. 2001;83:117-58 - PubMed
  11. Ann Surg. 1998 Sep;228(3):307-19 - PubMed
  12. Lancet. 2008 Aug 2;372(9636):383-91 - PubMed
  13. Cancer Res. 2006 Apr 1;66(7):3381-5 - PubMed
  14. J Clin Oncol. 2006 May 20;24(15):2283-9 - PubMed
  15. Cancer Res. 2010 Oct 15;70(20):7788-99 - PubMed
  16. Cancer Res. 2008 Sep 1;68(17):7025-34 - PubMed
  17. Lancet. 1994 Oct 15;344(8929):1049-52 - PubMed
  18. Immunity. 1996 Jun;4(6):535-43 - PubMed
  19. Lancet Oncol. 2012 Jan;13(1):e32-42 - PubMed
  20. J Clin Invest. 2007 May;117(5):1147-54 - PubMed
  21. Br Med Bull. 1964 May;20:154-8 - PubMed
  22. J Clin Invest. 2011 May;121(5):1797-809 - PubMed
  23. Br Med J. 1957 Apr 6;1(5022):779-86 - PubMed
  24. Science. 1991 Dec 13;254(5038):1643-7 - PubMed
  25. N Engl J Med. 2006 Feb 16;354(7):709-18 - PubMed
  26. Acta Histochem. 2006;108(1):19-24 - PubMed
  27. Science. 1995 Nov 10;270(5238):985-8 - PubMed
  28. N Engl J Med. 2012 Jun 28;366(26):2443-54 - PubMed
  29. J Exp Med. 2009 May 11;206(5):1103-16 - PubMed
  30. J Clin Oncol. 2001 Aug 1;19(15):3477-82 - PubMed
  31. N Engl J Med. 1988 Jun 16;318(24):1557-63 - PubMed
  32. Sci Transl Med. 2012 Mar 14;4(125):125sr1 - PubMed
  33. N Engl J Med. 2006 Sep 7;355(10):1018-28 - PubMed
  34. J Clin Oncol. 2012 Jul 20;30(21):2691-7 - PubMed
  35. PLoS One. 2012;7(10):e48424 - PubMed
  36. Mol Oncol. 2011 Apr;5(2):183-9 - PubMed
  37. Cancer. 1994 Mar 15;73(6):1621-4 - PubMed
  38. Clin Dev Immunol. 2012;2012:269756 - PubMed
  39. Lancet Oncol. 2012 Sep;13(9):879-86 - PubMed
  40. Clin Cancer Res. 2010 May 15;16(10 ):2861-71 - PubMed
  41. Clin Cancer Res. 2007 Apr 15;13(8):2422-8 - PubMed
  42. Clin Transplant. 1997 Dec;11(6):565-8 - PubMed
  43. Science. 1992 Aug 7;257(5071):789-92 - PubMed
  44. J Exp Med. 2006 Apr 17;203(4):883-95 - PubMed
  45. Nature. 2007 Mar 8;446(7132):153-8 - PubMed
  46. Science. 1993 Nov 5;262(5135):905-7 - PubMed
  47. Melanoma Res. 2005 Feb;15(1):77-82 - PubMed
  48. Science. 1993 Nov 5;262(5135):907-9 - PubMed
  49. J Immunol. 2004 Jul 15;173(2):1444-53 - PubMed
  50. J Immunol. 1994 Jul 1;153(1):429-35 - PubMed
  51. Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):10113-8 - PubMed
  52. Cancer Res. 2008 Feb 1;68(3):889-92 - PubMed
  53. Nat Genet. 2012 Sep;44(9):1006-14 - PubMed
  54. Science. 2007 Nov 16;318(5853):1108-13 - PubMed
  55. Clin Cancer Res. 2005 Apr 15;11(8):2947-53 - PubMed
  56. J Clin Oncol. 1999 Jul;17(7):2105-16 - PubMed
  57. Science. 2008 Oct 10;322(5899):271-5 - PubMed
  58. Br J Dermatol. 2013 Jan;168(1):162-71 - PubMed
  59. Nat Rev Cancer. 2012 Mar 22;12(4):252-64 - PubMed
  60. J Clin Invest. 2007 Sep;117(9):2570-82 - PubMed
  61. N Engl J Med. 2010 Aug 19;363(8):711-23 - PubMed
  62. PLoS One. 2010 May 03;5(5):e10436 - PubMed
  63. Clin Cancer Res. 2004 Mar 1;10 (5):1670-7 - PubMed
  64. Curr Opin Immunol. 1992 Oct;4(5):603-7 - PubMed
  65. Proc Natl Acad Sci U S A. 1984 Jun;81(11):3511-5 - PubMed
  66. Nature. 2006 Feb 9;439(7077):682-7 - PubMed
  67. Clin Exp Immunol. 2009 Jul;157(1):9-19 - PubMed
  68. Immunity. 1999 Aug;11(2):141-51 - PubMed
  69. N Engl J Med. 2011 Jun 30;364(26):2517-26 - PubMed
  70. J Exp Med. 1989 Sep 1;170(3):797-810 - PubMed
  71. Nature. 2012 Feb 08;482(7385):400-4 - PubMed
  72. Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20884-9 - PubMed
  73. Oncoimmunology. 2013 Feb 1;2(2):e23036 - PubMed
  74. Curr Opin Immunol. 2001 Apr;13(2):134-40 - PubMed
  75. J Immunol. 2000 Aug 1;165(3):1352-6 - PubMed
  76. J Exp Med. 2004 Sep 20;200(6):771-82 - PubMed
  77. Clin Cancer Res. 2012 Apr 1;18(7):2039-47 - PubMed
  78. J Immunol. 2009 May 1;182(9):5240-9 - PubMed
  79. Cancer Res. 2009 Aug 1;69(15):6011-4 - PubMed
  80. N Engl J Med. 2013 Apr 4;368(14 ):1365-6 - PubMed
  81. Nat Genet. 2009 Aug;41(8):920-5 - PubMed
  82. Science. 2002 Oct 25;298(5594):850-4 - PubMed
  83. J Clin Endocrinol Metab. 2007 Aug;92(8):3162-70 - PubMed
  84. Nature. 1993 Nov 4;366(6450):76-9 - PubMed
  85. J Exp Med. 1998 Sep 21;188(6):1203-8 - PubMed
  86. J Exp Med. 1997 Feb 3;185(3):393-403 - PubMed
  87. Cancer Res. 2005 Feb 1;65(3):1089-96 - PubMed
  88. Science. 2011 Apr 29;332(6029):600-3 - PubMed
  89. J Clin Oncol. 1993 Jul;11(7):1376-83 - PubMed
  90. J Clin Invest. 2002 Apr;109(7):923-30 - PubMed
  91. PLoS One. 2011 Apr 25;6(4):e18907 - PubMed
  92. J Exp Med. 1999 Aug 2;190(3):355-66 - PubMed
  93. N Engl J Med. 1985 Dec 5;313(23):1485-92 - PubMed
  94. Semin Oncol. 2010 Oct;37(5):508-16 - PubMed
  95. J Immunol. 2008 May 1;180(9):5916-26 - PubMed
  96. Nat Genet. 2008 Jul;40(7):886-91 - PubMed
  97. J Clin Oncol. 2008 Nov 10;26(32):5233-9 - PubMed
  98. Annu Rev Immunol. 2006;24:175-208 - PubMed
  99. Int J Cancer. 1998 Feb 9;75(4):517-24 - PubMed
  100. J Clin Oncol. 2005 Sep 1;23(25):6043-53 - PubMed
  101. Transplantation. 1996 Jan 27;61(2):274-8 - PubMed
  102. Ann Oncol. 2010 Feb;21(2):409-14 - PubMed
  103. J Exp Med. 2010 Sep 27;207 (10 ):2175-86 - PubMed
  104. J Clin Oncol. 2012 Nov 1;30(31):3810-8 - PubMed
  105. J Clin Oncol. 1996 Jan;14 (1):7-17 - PubMed
  106. Cancer. 2010 Apr 1;116(7):1767-75 - PubMed
  107. Blood. 2006 Jul 15;108(2):426-31 - PubMed
  108. Am J Epidemiol. 2005 Jul 1;162(1):3-16 - PubMed
  109. Science. 1976 Sep 10;193(4257):1007-8 - PubMed
  110. Nature. 2001 Apr 26;410(6832):1107-11 - PubMed
  111. Sci Transl Med. 2012 Mar 28;4(127):127ra37 - PubMed
  112. J Clin Oncol. 2013 Feb 10;31(5):616-22 - PubMed
  113. N Engl J Med. 2005 Sep 15;353(11):1114-23 - PubMed
  114. J Exp Med. 1991 Sep 1;174(3):561-9 - PubMed
  115. Transplantation. 1998 Sep 15;66(5):655-61 - PubMed
  116. Cancer Treat Rev. 2003 Aug;29(4):241-52 - PubMed
  117. Nat Med. 2002 Aug;8(8):793-800 - PubMed
  118. Oncol Rep. 2007 Nov;18(5):1115-22 - PubMed
  119. J Immunother. 2008 Jul-Aug;31(6):586-90 - PubMed
  120. J Am Acad Dermatol. 1983 Nov;9(5):689-96 - PubMed
  121. Nat Immunol. 2009 Feb;10(2):167-75 - PubMed
  122. N Engl J Med. 2010 May 6;362(18):1686-97 - PubMed
  123. Arthritis Rheum. 2011 Apr;63(4):939-48 - PubMed
  124. N Engl J Med. 2012 Jun 28;366(26):2455-65 - PubMed
  125. CA Cancer J Clin. 1976 Mar-Apr;26(2):119-21 - PubMed
  126. J Invest Dermatol. 2001 Dec;117(6):1464-70 - PubMed

Publication Types